BPI-2241

BPI-2241 is a highly effective, self-developed inhibitor of fibroblast growth factor receptor (FGFR). FGFR gene abnormalities—including amplification, mutation, and rearrangement—are implicated as pathogenic factors in many tumors and cancers. Amplification accounts for about 65% of these abnormalities, while mutations account for approximately 25%. In solid tumors, FGFR gene abnormality is a main pathogenic factor in about 10% of cases. FGFR inhibitors are considered to have broad potential across multiple cancer types; however, only two such drugs have been marketed globally (for bladder cancer and cholangiocarcinoma), with none yet approved in China. BPI-2241 is being developed by Beta Pharma as part of their oncology pipeline targeting various solid tumors[1][2][6].